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Abstract
Background: Therapies directed at augmenting regulatory T cell (Treg) activities in vivo as a systemic treatment for
autoimmune disorders and transplantation may be associated with significant off-target effects, including a generalized
immunosuppression that may compromise beneficial immune responses to infections and cancer cells. Adoptive cellular
therapies using purified expanded Tregs represents an attractive alternative to systemic treatments, with results from
animal studies noting increased therapeutic potency of antigen-specific Tregs over polyclonal populations. However,
current methodologies are limited in terms of the capacity to isolate and expand a sufficient quantity of endogenous
antigen-specific Tregs for therapeutic intervention. Moreover, FOXP3+ Tregs fall largely within the CD4+ T cell subset and
are thus routinely MHC class II-specific, whereas class I-specific Tregs may function optimally in vivo by facilitating direct
tissue recognition.
Methodology/Principal Findings: To overcome these limitations, we have developed a novel means for generating large
numbers of antigen-specific Tregs involving lentiviral T cell receptor (TCR) gene transfer into in vitro expanded polyclonal
natural Treg populations. Tregs redirected with a high-avidity class I-specific TCR were capable of recognizing the
melanoma antigen tyrosinase in the context of HLA-A*0201 and could be further enriched during the expansion process by
antigen-specific reactivation with peptide loaded artificial antigen presenting cells. These in vitro expanded Tregs continued
to express FOXP3 and functional TCRs, and maintained the capacity to suppress conventional T cell responses directed
against tyrosinase, as well as bystander T cell responses. Using this methodology in a model tumor system, murine Tregs
designed to express the tyrosinase TCR effectively blocked antigen-specific effector T cell (Teff) activity as determined by
tumor cell growth and luciferase reporter-based imaging.
Conclusions/Significance: These results support the feasibility of class I-restricted TCR transfer as a promising strategy to
redirect the functional properties of Tregs and provide for a more efficacious adoptive cell therapy.
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Introduction
Natural regulatory T cells (nTregs), defined by expression of the
transcription factors FOXP3 [1] and more recently Eos [2], play a
critical role in maintaining immune tolerance [3]. Recent interest
has been directed at this population as a means for providing
cellular therapy in settings of both autoimmunity and transplan-
tation [4]. In comparison, relatively non-specific therapies such as
anti-CD3, anti-thymocyte globulin, cytokines, and adhesion
molecule based agents are associated with significant non-specific
immunological effects and side-effects. Despite these limitations,
important mechanistic findings have emerged from these immune
therapies. First, short term modulation of T cells can elicit long-
term effects on immune tolerance [5]. Second, many of these
agents thought to provide long-lived efficacy are considered to do
so through promoting Treg subsets [6].
Treg transfers have been shown to effectively prevent or even
reverse disease, which is especially interesting in settings of
autoimmunity where such disorders are thought to result from the
genetic absence or loss of Tregs from the periphery [7,8]. A growing
list of potential mechanisms of action for Tregs includes both cell-
cell contact dependent and independent mechanisms (reviewed in
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[9]). From these numerous pathways, a common theme has
emerged that Tregs function by multiple mechanisms at the site
of antigen presentation; both in draining lymphoid tissue and at the
site of inflammation, to create a regulatory milieu that promotes
bystander suppression and infectious tolerance [10,11]. In other
words, activated Tregs are capable of suppressing cells recognizing
common, as well as unrelated antigens in the local microenviron-
ment and function to direct the development of activated
conventional T cells (Tconv) toward a tolerant state. Discovering
of the importance of Tregs in maintaining immune tolerance has
opened a potentially new means of therapeutic intervention in
immunology – namely, adoptive Treg therapy [12].
The concept of adoptive cell transfer initially emerged in the
mid-1950s as a means to manipulate immune responses in the field
of cancer therapy [13]. Cellular therapies have also been
employed in patients with HIV using co-stimulated CD4+ T cells
[14], as well as in the reconstitution of T cells following autologous
and allogeneic stem cell transplantation [15]. While these
treatments were designed to augment immune responses or stem
cell recovery, a related approach involving transfer of T cells,
specifically Tregs, has been employed to modify the immune
response in autoimmune settings. The transfer of T cells from
tolerized mice can prevent and/or reverse autoimmune disease
[16]. The efficacy of transferred Tregs as a therapeutic modality
has been demonstrated in animal models of systemic lupus
erythematosus (SLE) [17], multiple sclerosis (MS) [18], inflamma-
tory bowel disease (IBD) [19], oophoritis [20], and type 1 diabetes
(T1D) [21,22,23], among others.
Although the therapeutic potential for Treg-based therapies is
now well-established in animal models, to date adoptive Treg
therapy has not been directly applied to suppress autoimmunity in
humans. A number of challenges exist that need to be overcome in
order to employ these cells in clinical settings, including the need for
robust methods to isolate and expand this rare population. We
recently described a clinically-relevant FACS-based isolation and in
vitro expansion procedure for generating Tregs from patients with
T1D using the markers CD4, CD25 (IL-2 receptor a-chain), and
CD127 (IL-7 receptor a-chain) [24]. This approach was based on
the observation that CD127 is inversely correlated with FOXP3
expression in humans [25,26]. Utilizing this method, we demon-
strated that isolation of the CD4+CD127lo/2CD25+T cell fraction
yields an enriched population of Tregs that can be stably expanded
in vitro without the need for additional selective agents [25].
As previously discussed, numerous examples exist that antigen-
specific Tregs are more effective in several autoimmune syndromes
when compared to polyclonal populations [21]. With this, a major
challenge in antigen-specific Treg therapy in humans lies in the
isolation of sufficient quantities of antigen-specific T cells - a
challenge that is not easily overcome in humans where sampling is
largely limited to peripheral blood. Limited but appreciable
progress has recently been made to address this need including the
development of reagents allowing for specific labeling of known
antigen-specific T cells (e.g., peptide-MHC multimer staining of
autoreactive cells); however, this approach is limited by several
factors including the frequency of antigen-specific T cells in the
periphery and the limited availability of appropriate peptide-
MHC multimers. Adaptive Treg, such as those of the TR1- or
TH3-type, can be generated from Tconv cell populations by
culture under selective growth media conditions (e.g., rapamycin,
retinoic acid, TGF-b or IL-10) [27]. Other efforts to overcome
limited cell numbers have focused on delivering the transcription
factor FOXP3 to Tconv cell populations [28]. However, both of
these approaches to generate de novo Tregs are not without
limitations. Specifically, adaptive Treg populations often lack the
epigenetic profile of nTregs (i.e., they are often methylated at the
FOXP3-Treg specific demethylation region (reviewed in [29]),
bringing their stability in vivo into question. In the case of FOXP3
gene transfer, expression of the transcription factor is required for
Treg development, however transfer of FOXP3 to Tconv cells does
not recapitulate the full repertoire of transcripts and functional
characteristics of nTregs [30]. Therefore, the approach we took
was to initiate efforts with a fully mature polyclonal nTreg
population isolated from peripheral blood and redirect cell
specificity by viral TCR gene transfer. This approach has been
employed previously as a cancer immunotherapy studies which
showed that TCR a and b-chains could be introduced into CD4+
and CD8+ T cells in order to create a tumor-directed Teff cell
population that upon adoptive transfer destroyed pre-existing
tumor mass [31]. This approach has been shown to augment the
therapeutic profile of mouse Tregs in an arthritis model [32], as
well as redirect human Tregs using a chimeric immunoreceptor
[33]. In this study, we demonstrate that the specificity of
polyclonal human natural Tregs can be redirected by lentiviral
TCR gene transfer. Moreover, we demonstrate in a proof-of-
principal study that CD4+ Tregs can be engineered with class I-
specific TCRs capable of suppressing immunity in vivo.
Results
Generation of a lentiviral expression vector expressing a
tumor-specific TCR
To express de novo TCRs in Tregs, we first generated an
expression vector employing a previously characterized tumor-
reactive TCR (TyrTCR) that recognizes the melanoma antigen
tyrosinase in the context of the MHC class I molecule HLA-
A*0201 [34]. The multicystronic expression vector allowed for
equimolar TCR a and b chains by the inclusion of a T2A element
[35] followed by an IRES element and eGFP reporter
(Figure 1A). This receptor functions independently of the co-
receptor; allowing for productive TCR signaling in CD4+ T cells
[34,36,37]. Lentiviral transduction of Jurkat T cells was detected
by flow cytometric analysis based on GFP reporter and tyrosinase-
specific TCR Vb12 expression (Figure 1B). Signaling by the
introduced TCR was further validated by upregulation of CD69
and production of IL-2 following stimulation with artificial antigen
presenting cells (aAPC, K562 cell line expressing HLA-A2, CD80,
and CD83) and tyrosinase peptide (Figure 1C,D).
Stability and functional capacity of TCR-redirected
primary human CD4 T cells
Given our ability to express a functional TCR in Jurkat T cells,
we next sought to validate expression in primary human CD4+ T
cells. Freshly isolated human CD4+ T cells were activated for
48 hr with anti-CD3 and anti-CD28-coated beads prior to
transduction with lentivirus expressing the TyrTCR. GFP and
TCR Vb12 co-expressing cells were isolated by fluorescence-based
cell sorting (Figure 2A). Expression of surface TCR was stable
following in vitro expansion (Figure 2B) and the TyrTCR-
transduced cells responded specifically to tyrosinase peptide in a
dose-responsive fashion. No proliferation was observed from the
native GFP2Vb12+ sorted population stimulated with tyrosinase
peptide or from the GFP+Vb12+ T cell population incubated with
an irrelevant HLA-A*201-restricted control peptide (MART-1)
(Figure 2C,D). Cytokine production (IFN-c, IL-10) by TyrTCR-
transduced cells was also detected following co-culture with a
melanoma tumor cell line expressing tyrosinase naturally pro-
cessed and presented in the context of HLA-A*0201 (data not
shown). The successful de novo expression of a functional TCR in
Engineered Human Tregs
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primary human CD4+ T cells facilitated the subsequent targeting
of this receptor to Tregs.
Generation of engineered human Treg and Tconv cells
We recently described a clinically-relevant FACS-based isola-
tion and in vitro expansion procedure for generating Tregs
enriched in FOXP3 expression in humans [25]. Utilizing this
method, we demonstrated that isolation of the CD4+CD127lo/
2CD25+ T cells yielded a highly enriched population of Tregs that
are greater than 90–95% FOXP3+ [24]. Subsequent studies
suggested that the inclusion of CD45RA as a positive selection
marker resulted in greater enrichment of FOXP3+ T cells and
maximum stability following in vitro expansion [38,39] (Figure
S1). The purity and stability of this sorted population was further
validated by assessing FOXP3 protein and FOXP3 promoter
methylation status following in vitro expansion. Prior reports have
suggested that only bona-fide nTregs remain demethylated at the
FOXP3 gene Treg-specific demethylation region (TSDR) [40].
CD45RA+ Tregs were determined to be FOXP3+ by FACS
(mean+SD, 92.3+9.6%, N = 8) and demethylated at the TSDR
(91.0+15.3%) following a 14 day expansion period, demonstrating
the specific expansion of the nTreg subset (Figure S1G).
Next, the polyclonal population of purified nTregs was infected
with lentivirus expressing a GFP reporter following activation as
described in Materials and Methods. High levels of GFP
expression were detected following in vitro expansion with no
significant reduction in expansion capacity or suppressive function
(Figure S2). Given the high efficiency of transgene expression in
Tregs, we subsequently transduced a population of purified naı¨ve
Tregs and Tconv cells with a lentiviral TyrTCR construct. Freshly
sorted cells were activated for 48 hr in vitro prior to a single
infection with lentivirus encoding the TyrTCR. Surface TCR and
tetramer staining, along with GFP reporter expression were
analyzed by flow cytometry at day nine of the in vitro expansion
period. Initial transduction of Tregs resulted in a degree of
heterogeneity in the level of TCR and GFP reporter expression.
Flow cytometric analysis indicated 20.7616.6% of cells expressed
eGFP, whereas 13.2614.5% of cells were GFP+Vb12+ following
nine days of in vitro expansion (N= 10). Surface expression of TCR
Vb12 might not indicate functional receptor expression, given the
possibility for heterologous pairing with endogenous TCR a and b
chains [41]. To further validate proper surface expression, HLA-
A*201-tyrosinase tetramer staining of transduced Tregs revealed
33.5% of cells were GFP+TyrTCR tetramer+, whereas 16.8% of
Tconv cells were GFP+TyrTCR tetramer+ (Figure S3B).
We observed that increasing lentiviral titer led to only modest
increases in the number of cells expressing functional receptors
(data not shown). Therefore, we sought to enrich antigen-specific
T cells while limiting non-specific growth, as previously described
[42]. At day nine, cells expressing the TyrTCR were restimulated
with aAPCs and tyrosinase peptide. This antigen-specific activa-
tion led to enrichment of the transduced cells with 66.1% of Treg
and 50.3% of Tconv cells expressing both GFP and the TyrTCR
Figure 1. Lentiviral TCR expression construct and receptor validation in Jurkat T cells. (A) The tyrosinase TCR expression vector consists of
a pSICO backbone, which has been modified to express the TCR a and b receptors derived from a CD4+ tumor infiltrating lymphocyte (clone TIL
I383I). The resulting construct drives TCR-a and TCR-b proteins under the MND promoter from a single 2A peptide-linked tricistronic lentiviral vector
followed by an eGFP reporter. (B) Human Jurkat T cells were transduced with the lentiviral construct by spin infection and sorted for the tyrosinase
reactive TCR 72 h post-transduction. Sorted and Vb12+GFP+ or mock transduced cells were then tested for their capacity to respond to their cognate
peptide presented by artificial APCs (aAPCs). These K562-derived aAPCs present peptide in the context of human HLA-A*0201 along with the
costimulatory/adaptor molecules CD80 and CD83. (C) Vb12+GFP+ Jurkat T cells upregulate CD69 following 24 h exposure to [Asp370]-tyrosinase(368–
376) peptide (0.1 mg/ml) (red histograms) but not in response to the irrelevant HLA-A*0201 presented Melan-A/MART-1(27–35) peptide (green
histograms). (D) Culture supernatants from peptide stimulated Jurkat T cells were collected following 24 h of culture and analyzed for production of
IL-2 by ELISA.
doi:10.1371/journal.pone.0011726.g001
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(Figure 3A,B). Mock transduced cells were restimulated by anti-
CD3 and anti-CD28 coated beads. The expansion capacity of
TyrTCR Tregs expanded on aAPC and peptide was dependent
upon the initial transduction efficiency (N= 3; median 480-fold,
range 240 to 1088-fold). Of note, we were able to obtain .5200-
fold expansion of TyrTCR+ Tregs yielding 1.186109 cells (89.3%
eGFP+, 91.7% FOXP3+), from an initial blood volume of 80 ml by
extending the culture to day 20 (data not shown).
Following expansion, 96.4% of mock-transduced Tregs stained
positive for FOXP3 protein by FACS with 100% of cells
remaining demethylated at the FOXP3-TSDR for the sample
shown (Figure 3C, upper panel). By comparison, 98.2% of
TyrTCR-transduced Tregs stained positive for FOXP3 protein
by FACS with 99.1% of cells remaining demethylated at the
FOXP3-TSDR (Figure 3D, upper panel). As a population, Tregs
expressing the TyrTCR expressed comparable levels of FOXP3
(95.662.0) in comparison to mock Tregs (93.662.3; N = 8,
P = not significant). It is interesting to note that Tconv cells
expanded poorly under our Treg growth conditions and tended
to upregulate FOXP3 protein as determined by FACS
(33.8617.9 vs 35.9622.8 for mock and TyrTCR, respectively,
N = 3). Despite this induction of FOXP3 protein, epigenetic
analysis of the FOXP3-TSDR indicated the absence of bona-fide
Tregs (0.02% and 2.81% demethylated for mock and TyrTCR
Tconv cells, respectively, Figure 3C,D). This observation
highlights the need for monitoring of the methylation status of
the FOXP3-TSDR as a stringent quantitative measure of cell
purity post-expansion [43].
Figure 2. Isolation and characterization of lentiviral transduced primary human CD4+ T cells expressing the tyrosinase-reactive
TCR. (A) Human CD4+ T cells were isolated by negative selection from fresh peripheral blood and activated for 48 h in the presence of anti-CD3 and
anti-CD28 coated microbeads and human IL-2 (300 IU/ml). Cells were spin infected 48 h post-transduction and assessed for TCR Vb12 and GFP
expression by FACS 72 hr post-transduction (A, upper-left hand plot). Individual cell populations (column A plots) were FACS sorted based on
expression TCR Vb12 and GFP (Vb12+GFP+, upper-right quadrant; Vb122GFP+, lower-right; Vb122GFP2, lower-left). Each sorted population was
expanded in culture for 12 d and then assessed for stability of (B) TCR Vb12 and GFP expression by FACS and (C) proliferation assessed by 3H-
thymidine incorporation in response to peptide presented in the context of HLA-A*0201 expressing aAPCs. T cell populations (26104 cells/well) were
stimulated by culturing 56105 irradiated (10,000 rads) aAPCs with soluble peptide as indicated (C and D). Proliferation is graphed as the mean6SD
from triplicate wells. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0011726.g002
Engineered Human Tregs
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Functional capacity of engineered Tregs
The capacity of expanded TCR-transduced Tregs to suppress
proliferation of freshly isolated conventional CD4+ T cells was
examined following stimulation with anti-CD3 and anti-CD28.
GFP+TyrTCR+ Tregs were FACS sorted following 14 days of in
vitro expansion and mixed at indicated ratios of Tregs to Tconv
cells. TyrTCR Tregs suppressed polyclonal T cell proliferation
potently and in a dose-responsive fashion (Figure 4A). We next
tested the capacity of TyrTCR Tregs to suppress antigen-specific
CD4+CD127+CD252 Tconv cell responses. Following expansion,
Treg and Tconv GFP+TyrTCR+ cells were sorted from expanded
cultures and restimulated with tyrosinase peptide in the presence
of aAPCs (Figure 4B). TyrTCR-expressing Tregs were capable of
suppressing Teff cell responses in an antigen-specific fashion.
The therapeutic efficacy of Tregs depends on their capacity to
suppress an array of T cell responses in a bystander fashion, as well
as antigen-specific fashion. In order to address this issue, we tested
the capacity of TyrTCR-transduced Tregs to suppress prolifera-
Figure 3. Expression of tyrosinase TCR constructs by in vitro expanded human Treg and Tconv cells. Plots indicate expression of surface
TCR, GFP, and FOXP3 following 14 day in vitro expansion period for mock or TyrTCR transduced Treg and Tconv cells. Fresh human PBMCs were
sorted by FACS to yield CD4+CD1272/loCD25+CD45RA+ Tregs and CD4+CD127+CD252CD45RA+ Tconv cell populations and stimulated with anti-CD3
and anti-CD28 microbeads for 48 hours prior to lentiviral spinoculation. Following eight days of in vitro expansion, mock transduced cells were
restimulated with microbeads and TyrTCR transduced T cells were enriched by restimulation with aAPCs and soluble tyrosinase peptide (0.1 mg/ml).
Plots indicate expression of eGFP (y-axis) and TCR Vb12 or HLA-A2 tyrosinase(368–376) tetramer staining (x-axis) with (A, upper plots) representing mock
transduced cells and (B, lower plots) showing TyrTCR transduced populations. Histograms overlays indicate isotype control staining (red histograms) or
FOXP3 staining (green histograms) of mock or TyrTCR transduced populations. Data shown represent one subject of ten independent experiments
following lentiviral TyrTCR transduction of Tregs.
doi:10.1371/journal.pone.0011726.g003
Engineered Human Tregs
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tion of hemagglutinin (HA) peptide-reactive Teff cells. To generate
human HA-reactive Teff cells, we labeled PBMCs from a HLA-
DR*0401 individual with CFSE and stimulated with HA
peptide(306–318) to induce expansion of endogenous HA-specific
T cells. Following 14 day expansion, CFSE-diluted cells (.13%
HLA-DR*0401 HA-tetramer+; data not shown) were used as
responding Teff cells in subsequent assays. For suppression assays,
TyrTCR Tregs were stimulated in the context of HLA-A*0201,
while the responding Teff cells were stimulated in the context of
HLA class II DR*0401 APCs incubated with HA peptide(306–318).
To test the specific activation requirements of Tregs in mediating
bystander suppression, TyrTCR-transduced Tregs were stimulat-
ed with tyrosinase peptide or the irrelevant HLA-A*0201
restricted MART-1 peptide. This analysis indicated that
TyrTCR-transduced Tregs were indeed capable of suppressing
HA-reactive Teff cell proliferation in a bystander fashion and
demonstrated that TyrTCR cells maintained optimal potency
when activated specifically through the introduced TCR
(Figure 4C). This was particularly apparent at lower and more
physiological ratios of Tregs to Teff cells (i.e. 1/4:1,
1/8:1, and
1/16:1) (Figure 4D). Despite this increased potency, we observed
some antigen non-specific suppression by TyrTCR Tregs in vitro
(particularly at higher Treg to Teff cell ratios, i.e. 1:1), suggesting
that Tregs may not be fully rested following the activation received
during the in vitro expansion protocol. We also analyzed the ability
of TyrTCR Tregs to influence cytokine production (e.g. IFN-c,
IL-2, and IL-10) when co-incubated with a tumor infiltrating cell
line (TIL1235) and peptide pulsed APCs. Consistent with our prior
investigations [24,44], TyrTCR transduced Tregs suppressed
effector T cell cytokine production in a dose-responsive fashion
for IFN-c and IL-2. Interestingly, the reciprocal cytokine
production profile was seen for IL-10, wherein co-cultures with
TyrTCR Tregs, but not mock Tregs produced the highest levels of
this immunoregulatory cytokine (Figure S4). While in vitro
suppressive activity is an important indication of Treg function,
it does not reflect the full activity of Tregs in vivo. Therefore, we
sought to test whether TCR-transduced Tregs were capable of
suppressing T cell-mediated tissue damage in vivo.
In vivo activity of TyrTCR expressing Tregs
We employed a tumor model system to assess the in vivo function
of TyrTCR-redirected Tregs. EL-4-HLA-A2/Kb tumors express-
ing tyrosinase were transferred into HLA-A2/Kb transgenic mice.
Mice were then separated into groups receiving in vitro expanded
murine TyrTCR Tregs, mock vector-transduced Tregs, or control
vector-transduced Teff cells via intravenous injection. All mice
received antigen-specific Teff cells expressing the TyrTCR. These
TyrTCR Teff cells could be tracked in vivo by a firefly-Luciferase
(fLuc) reporter element encoded within the expression construct
(Figure 5A). The murine TyrTCR expression construct was
modified for optimized surface expression and improved tetramer
reactivity (R. Koya, unpublished observations). Specifically, the
Figure 4. In vitro suppressive capacity of lentiviral transduced Tregs expressing the tyrosinase TCR. TyrTCR transduced Treg and Tconv
cells were sorted to enrich the GFP+Vb12+ cell population (as indicated in Fig. 2A). The sorted Tregs were then tested for their capacity to suppress
proliferation of autologous expanded Tconv cells during in vitro suppression assays following both polyclonal and antigen-specific T cell activation.
(A) FACS sorted GFP+Vb12+ Treg cells suppress proliferation of anti-CD3 and anti-CD28 stimulated GFP+Vb12+ Tconv cells in a dose-responsive
manner. (B) In vitro expanded Tregs suppress TyrTCR GFP+Vb12+ Tconv cells stimulated by aAPCs and tyrosinase peptide. (C) A representative
suppression assay demonstrating GFP+Vb12+ Tregs are more potent at suppressing autologous hemagglutinin (HA)-reactive Teff cells when
stimulated by their cognate antigen compared to an irrelevant HLA-A2 restricted peptide. HA-reactive Teff cells were stimulated by HLA-DR*0401
expressing APCs and HA peptide with Tregs stimulated with either tyrosinase peptide (C, closed bars) or an irrelevant HLA-A*0201 restricted peptide
melan-A (MART-1) (C, open bars). (D) Percent suppression of HA-reactive Teff cells stimulated in the presence of Tyr-Tregs activated by tyrosinase
peptide (black bars) or MART-1 (open bars) (N= 3 independent experiments, *P,0.05). Shown are mean6SEM.
doi:10.1371/journal.pone.0011726.g004
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TyrTCR construct was modified to express murine TCR constant
regions and human TCR variable regions [34]. Additional
modifications consisted of introducing cysteine residues to the
TCR a and b chains to induce disulfide linkages, 2A peptide linker
sequences, and leucine zipper motifs between TCR chains as
described in Materials and Methods. The modified TyrTCR could
be expressed on murine CD4+ T cells with expression by
expanded Tregs verified by HLA-A*201-Tyrosinase(368–376) tetra-
mer staining following in vitro expansion with anti-CD3 and anti-
CD28-coated microbeads and IL-2 (Figure 5B).
We monitored the expansion and distribution of TyrTCR-
expressing Teff cells using an in vivo luciferase reporter in treatment
groups receiving TyrTregs, mock-vector transduced Tregs, or
mock-vector transduced Teff cells. Imaging during the experi-
mental time-course revealed broad TyrTCR Teff cell distribution
and tumor infiltration in mice receiving either polyclonal Tregs or
Figure 5. Tyrosinase TCR transduced Tregs block antigen-specific effector T cell activity in vivo. Eight-weeks old HLA-A2/Kb transgenic
mice were injected subcutaneously (s.c.) with EL4-A2/Kb tyrosinase protein expressing tumors (5 mm in diameter) in the inguinal fat pad. Murine T
cells were transduced with MSCV-based retroviral vectors encoding the Tyrosinase TCR with (A) Firefly Luciferase (fLuc) reporter for Teff cells or
HSVtk/GFP reporter for Tregs. Mice were randomized into three groups receiving in vitro expanded Tregs transduced with TyrTCR/TK/GFP vector
(TyrTCR Tregs), polyclonal mock Tregs (Untrd, Treg), or mock T effector cells (Untrd, Teff). (B) Mock or HLA-A*0201(368–376) tetramer staining of TyrTCR
transduced Tregs prior to injection. Following 24 hours, all mice received Teff cells transduced with Tyr-TCR/fLuciferase reporter. (C) Luciferase-based
in vivo bioluminescence imaging (BLI) was performed for imaging of fLuc-transduced Teff cells. Fluorescence images of treatment groups are shown
at day 8. (D) The mean number of photons per square centimeter per second per steradian in the region of interest (ROI) was determined on tumor-
implanted sites for mice receiving TyrTCR Tregs (blue square), Untransduced Tregs (red circle), and Untrd Teff (green triangle). (E) Tumor site volume
(mm3) assessed by caliper measurement for adoptive cell transfer treatment groups. Data shown is representative of two independent experiments
with *P,0.05, **P,0.01, and ***P,0.0001 assessed by Two-way ANOVA with Bonferroni correction.
doi:10.1371/journal.pone.0011726.g005
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Teff cells (Figure 5C). In contrast, TyrTCR Teff cell expansion
was restricted in mice receiving antigen-specific TyrTCR Tregs.
This was most apparent at day eight post transfer with 5.66105,
3.16106, and 3.96106photons/sec/cm2/sr detected for TyrTCR
Treg, polyclonal Treg, and Teff cells, respectively (Figure 5D).
No significant difference in luciferase reporter was detected
between Teff and polyclonal Treg treated mice.
TyrTCR-redirected Teff cells are highly effective at facilitating
tumor regression upon transfer. We tested the capacity of antigen-
specific Tregs to block tumor immunity in mice receiving TyrTCR
Tregs, polyclonal Tregs, or control Teff cells. Mice receiving
TyrTCR-redirected Tregs effectively blocked TyrTCR Teff cell-
mediated tumor rejection as determined by tumor size
(Figure 5E). In contrast, a partial suppressive effect was observed
in mice treated with polyclonal Tregs, with near complete tumor
rejection observed in mice receiving Teff cells alone. These data
argue that TCR-redirected Tregs are indeed capable of suppress-
ing Teff cell responses in vivo, and further demonstrate that
antigen-specific Tregs are more potent than polyclonal Tregs in
limiting Teff-cell mediated tissue destruction.
Discussion
Here we describe a novel method to generate therapeutically
relevant numbers of antigen-specific human Tregs. These TCR-
redirected Tregs can be selectively enriched in vitro by reactivation
with APCs and peptide to reach clinically viable cell numbers (i.e.,
in the range of 109 cells) [12]. Lentiviral infected Tregs expand
with similar kinetics to mock-infected Tregs and maintain the
phenotypic and functional characteristics of nTregs in vitro.
Specifically, antigen-specific Tregs suppressed Teff cells recogniz-
ing a common antigen (tyrosinase), in addition to bystander Teff
cell responses. Importantly, the suppressive phenotype of human
Tregs expressing the TyrTCR was recapitulated in vivo using
murine Tregs and antigen-specific Teff cells.
Recent studies suggest that Tregs may exert direct tissue
protective effects, in addition to their ability to limit Teff cell
responses. Mechanistically, Tregs are thought to accomplish this
through enzymatic pathways that reduce oxidative stress and
produce anti-inflammatory byproducts [45,46,47,48]. Here we
show that Tregs can be directed to recognize MHC class I-
restricted antigens allowing direct tissue recognition by transfer of
a high-avidity TCR. This capability allows Treg activity to be
directed to specific tissue microenvironments and target tissues
deficient in APCs expressing MHC class II molecules. While not
specifically addressed here, the use of TCR gene transfer to Tregs
should facilitate studies addressing the optimal affinity of receptors
as well as the lineage stability of Tregs in humanized animal model
systems [49].
This technology opens up avenues for additional transgenes to
be transferred in addition to the TCR as therapeutic gene
cassettes. This approach could extend the function of engineered
Tregs beyond that of even native Tregs. For example, the desired
TCRs may be expressed along with a combination of immuno-
regulatory cytokines (IL-10 or TGF-b), chemokine receptors or
tissue-homing receptors, or even tissue regenerative growth factors
if necessary.
The use of viral gene transfer in Treg therapy settings confers
the ability to address several important safety concerns. First, while
a high purity of FOXP3+ Tregs was detected following our
expansion procedure, the concern remains that an autoreactive
TCR could potentially be expressed in a contaminating Teff cell
or a Treg cell that has lost regulatory function [50]. Our approach
could reinforce the regulatory program by the expression of
FOXP3, or other regulatory genes in our expression cassette.
Second, our system allows for the inclusion of inducible suicide
genes or depletion markers should situations involving leukemia or
pan-immunosuppression result.
One potential concern with this approach is the possibility for
mismatched pairing of the introduced a and b TCR chains with
the endogenous TCR subunits, resulting in reduced surface
expression and biological activity. Mismatched pairing of receptors
could potentially also generate harmful reactivities when expressed
in effector T cell subsets. Cohen and colleagues previously
addressed this issue by adding a single cysteine on each receptor
chain to promote the formation of an inter-chain disulfide bond
[51]. These cysteine-modified receptors retain their function and
lead to preferential pairing, thus interfering with heterologous
chain pairing between introduced and endogenous receptors [51].
Strategies such as codon optimization of TCR a and b chains have
also been used to optimize de novo TCR expression over the
endogenous receptors (reviewed [52]). The tyrosinase TCR used
in our animal model experiments incorporated many of these
modifications resulting in improved pairing and in vivo function.
In summary, novel gene therapy approaches, in concert with
the previously outlined cellular therapeutics may offer new
opportunities to generate antigen-specific tolerance by targeting
the regulatory properties of Tregs to specific antigen targest. Prior
studies employing adoptive cell therapy in the cancer setting imply
that large numbers of transferred cells may be required in order to
elicit a therapeutic effect [12,53]. Here we demonstrated a strategy
to efficiently generate therapeutic numbers of antigen-specific
Tregs from low starting peripheral blood volumes. Applications of
this strategy to engineer Tregs capable of recognizing autoantigens
targeted in T1D are currently underway, with the goal of
developing robust and targeted immunotherapies for the treat-
ment of autoimmune diseases and transplantation.
Materials and Methods
Ethics Statement
Informed written consents for patient studies were obtained in
accordance with the reviewed and approved policies and procedures
at the University of California, San Francisco (UCSF), and ethics
approval was granted by the UCSF Institutional Review Board
(approval number H7023-22712-08). Animal studies were approved
by the Animal Research Committee (ARC) of UCLA (approval
number 2004-159) and the Institutional Animal Care and Use
Committee (IACUC) of UCSF (approval number AN082188-01).
Animals were bred and maintained according to the guidelines of the
Department of Laboratory Animal Medicine (DLAM) at UCLA.
Patient Population
Patient samples were collected from normal healthy adult
subjects from the general population (N = 10; 5M/5F, median age
28.58 yr, range 20.71 to 34.71).
Sample processing
Fresh peripheral blood was collected in sodium heparinized
vacutainer tubes (BD; Franklin Lakes, NJ) and processed
immediately for isolation of lymphocyte subpopulations. Whole
blood was pre-enriched with the RosetteSep CD4+ negative
selection cocktail and processed according to manufacturer
recommendations (StemCell Technologies, Vancouver, BC,
Canada). As an additional purification step, CD4+ T cells were
incubated with CD45RO-biotinylated antibody (Leinco Technol-
ogies, St. Louis, MO; 0.1 mg/ml per 1610‘6 cells). CD45RO-
biotin labeled CD4+ T cells were then bound with BioMag
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streptavidin microbeads (50 ml/108 cells) followed by a 5 minute
incubation and subsequent depletion on the EasySep magnet
(StemCell). Untouched CD4+CD45RA+ T cells were then
resuspended at 16108 cells per ml and stained with antibodies
in PBS containing 10% FBS for FACS isolation.
Isolation of Tregs and Tconv cells by FACS
Tregs and Tconv cells were isolated on a BD FACSAria II high
speed cell sorter following the CD4+CD45RA+ pre-enrichment
(BD Biosciences, San Jose, CA) with the following antibodies:
CD4-PerCP (clone SK3), CD127-PE (hIL-7R-M21), and CD25-
APC (2A3) as previously described [24], with the addition of
CD45RA-PE-Cy7 (HI100) to select the naive Treg subset.
CD4+CD45RA+CD127lo/-CD25+ regulatory T cells (Tregs) and
CD4+CD45RA+CD127+CD252 conventional T cells (Tconv)
were sorted using aseptic technique in a cGMP-level clean room
facility and the sorted populations were collected into 2 ml of
RPMI 1640 (Mediatech, Manassas, VA) complete media contain-
ing 10% heat-inactivated FCS. Populations were analyzed for
purity post-sort and determined to be mean6SD, 98.5%61.07;
median 98.7%, range 95.8 to 99.7 for Tconv cells and 97.761.87;
range 93.8–99.6% for Tregs.
Lentiviral vectors for expression of TCRs
The generation of the tyrosinase TCR (TyrTCR) construct was
previously described [34,54]. Expression of the tyrosinase-reactive
TCR a and b-chain genes in Treg and Tconv cells was achieved
by cloning the TCR construct into the pSICO lentiviral vector
[35]. This receptor is derived from a CD4+ T cell but functions
independently of the co-receptor [34]. Equal molar expression of
TCR a and TCR b-chain genes was made possible by the
inclusion of a T2A expression element between the TCR a and b
chain genes [35]. A 1857 bp EcoRI-XhoI TyrTCR fragment was
generated by PCR from the original vector and ligated with a
1303 bp XhoI-NotI internal ribosome entry site (IRES) and eGFP
reporter gene into the pSICO backbone. The pSICO construct
was driven off the murine leukemia virus-derived MND promoter.
All constructs were validated by restriction enzyme digest and
sequence analysis.
In vitro expansion procedure
FACS isolated cells were plated at 2.56105 Tregs or Tconv cells per
well in a 24-well plate (Costar; Cambridge, MA) and activated with
anti-CD3/anti-CD28 coated microbeads (Invitrogen; Carlsbad, CA)
at a 1:1 bead to cell. At 48 hr, cultures were split into mock transduced
and lentiviral TCR transduced populations. Cultures were grown in
the presence of IL-2 following day 2 and continuing throughout the
14-day expansion period (300 IU/ml, Proleukin; Chiron Therapeu-
tics, Emeryville, CA). Cells were resuspended and fresh media and IL-
2 (300 IU/ml) added at days 5, 7, 9, and 12 assuming consumption of
IL-2. On day 9, cells were restimulated with fresh anti-CD3/anti-
CD28 coated beads for mock transduced cells at a 1:1 ratio or with
artificial APCs (aAPC), a K562 cells line expressing HLA-A*0201,
CD80, CD83 (A kind gift of Lee M. Nadler, Boston, MA) and soluble
tyrosinase peptide (0.1 mg/ml, [Asp370]-Tyrosinase(368–376); AnaSpec,
Inc., San Jose, CA). Cultured cells were harvested at day 14 for
analysis by FACS and functional studies.
Lentiviral production and transduction of T cells
Lentivirus was produced as previously described [54]. Activated
T cells were transduced 48 hr following polyclonal activation with
anti-CD3 and anti-CD28 coated microbeads (Dynal, Invitrogen).
2.56105 cells per well were transduced in one ml total volume of
fresh culture media in a 24-well plate containing lentivirus
(20 TU/cell) and protamine sulfate (8 mg/ml; Sigma-Aldrich, St.
Louis, MO). Cells were spinnoculated by centrifugation at 10006g
for 30 min at 32uC. Transgene expression was assessed no earlier
than 72 hrs post-transduction.
Phenotypic analysis of expanded human Treg
populations
Freshly expanded cells were evaluated for continued expression
of CD4 (SK3), eGFP, TCR Vb12 (clone VER2.32.1) or HLA-
A*0201 tyrosinase(YMDGTMSQV) tetramer (Beckman Coulter,
Fullerton CA). Anti-human FOXP3 (clone 206D) was purchased
from BioLegend (San Diego, CA) and intracellular staining
performed with the FOXP3 staining kit according to manufac-
turer’s instructions and modified as previously described [25].
Flow cytometric data was collected on a FACSCalibur cytometer
(BD Biosciences) and analyzed with FlowJo software (version 7.2.2,
TreeStar, Ashland, OR). Epigenetic analysis of the FOXP3-TSDR
was conducted by a methylation-sensitive real time PCR method
developed by Epiontis Corporation (Berlin, Germany).
In vitro stimulation and suppression assays
For the purposes of this study, suppression was assessed based
on the capacity of in vitro expanded Tregs to suppress the
proliferation of syngeneic Tconv cell populations. APCs were
provided by either autologous CD3 depleted (RosetteSep CD3
depletion cocktail, StemCell) HLA-A2+ (irradiated 3300 rads)
PBMC for polyclonal stimulation conditions or HLA-A2+/
CD80+/CD83+ K562-cell derived artificial APCs (irradiated
10,000 rads) for antigen-specific suppression assays. For polyclonal
suppression assays, cells were stimulated with 2 mg/ml soluble
anti-CD3 (Hit3a) and 1 mg/ml soluble anti-CD28 (28.2, BD
PharMingen). Soluble tyrosinase peptide(368–376) was added at
0.1 mg/ml for measuring antigen-specific suppression assays, with
melan-A peptide(27–35) (MART-1) used as an HLA-A*0201-
restricted negative control peptide (Anaspec). Cultures were
incubated for 4 days at 37uC in a 5% CO2 incubator. Proliferation
was determined by the incorporation of 3H-thymidine by pulsing
cultures with 1 mCi of 3H-thymidine for the final 12–16 h of
culture. Plates were harvested on a Packard FilterMate harvester
and read on a Packard TopCount Scintillation & Luminescence
Counter (Perkin Elmer; Waltham, MA). Percent suppression was
calculated as previously described [55].
Isolation and expansion of murine Tregs
CD4+CD25+CD62Lhigh Tregs were isolated from lymph nodes
and spleens of 8–10 week old female C57BL/6 mice. Cells were
pre-enriched with the mouse CD4+ T cell enrichment kit
according to manufacturer’s instructions (StemCell). Following
enrichment, cells were stained with anti-mouse CD4-PE-Cy7,
CD25-PE-Cy5, CD62L-FITC, and CD8-APC-Cy7 (as a dump
fluorescence channel). Cells were sorted on a MoFlo Cell Sorter
(Beckman Coulter) with two consecutive rounds of sorting to reach
high purity prior to in vitro expansion (Median 99.4%, range 99.1–
100). Cells were expanded in vitro by activation with Dynabead
mouse T cell activator anti-CD3 and anti-CD28 coated microbe-
ads (3:1 bead to Treg ratio, Invitrogen) with exogenous IL-2
(2000 IU/ml, Novartis) as previously described [23].
Retroviral transduction of murine T cells and adoptive
cell transfer (ACT)
High-titer retrovirus stocks were prepared by transient co-
transfection of Phoenix-Eco cells as previously described [56].
Engineered Human Tregs
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11726
Retroviral constructs were based on a MSCV vector backbone
containing a hybrid TyrTCR with complete murine constant
region substitutions, and addition of cysteine residues on each
chain as described [51]. Leucine zipper motif sequences were
added to the 39 terminus of each chain to improve pairing and 2A
sequences inserted between the TCR a, b chain, and marker
transgenes [35]. For effector T cell generation, cells from spleen
and lymph nodes of 8 weeks-old HLA-A2/Kb transgenic mice
were harvested and RBC-depleted with Red Blood Cell Lysing
Buffer (Hybri-Max, Sigma, St. Louis, MO). Cells were then
incubated in anti-CD3 and anti-CD28-coated plates (BD Biosci-
ences) for activation of T cells. At 48 hours post-activation, cells
underwent spinoculation with retrovirus supernatants (10 multi-
plicity of infection) in retronectin (Takara-bio, Shiga, Japan)-
coated plates at 10006g, 120 minutes, 32uC, in a Beckman CS-6R
centrifuge. The transduction procedure was repeated again
following 24 hours and incubated overnight. Cells were then
washed and re-suspended in culture media for analysis or in PBS
for injection. Eight-week old HLA-A2/Kb transgenic mice were
injected subcutaneously (s.c.) with EL4-A2/Kb cells expressing
tyrosinase protein were used for adoptive cell transfer when the
tumors reached 5 mm in diameter. Mice were conditioned with
myeloablation (900 cGy total-body irradiation), followed by rescue
with intravenous injection of 106 total bone marrow cells. On the
next day (day 0), mice were randomized into control groups with
Treg cells and T effector cells transduced with control mock vector
and treatment group with Treg cells transduced with Tyr-TCR/
TK/GFP vector for intravenous injection. Dendritic cells (DC)
were differentiated from bone marrow progenitor cells obtained
from HLA-A2/Kb mice by in vitro culture in murine granulocyte
macrophage colony-stimulating factor (GM-CSF, 50 ng/ml) and
murine IL-4 (50 ng/ml; R&D Systems, Minneapolis, MN) as
described [57]. DCs were harvested as loosely adherent cells,
washed twice in PBS (Mediatech) and pulsed with tyrosinase(368–
376) peptide at a concentration of 10 mM in serum-free media for
90 minutes at room temperature. Each mouse received 105 pulsed
DCs given s.c. on day 0. On day 2, all mice received T effector
cells transduced with Tyr-TCR/firefly (f)Luciferase vector intra-
venously. Recombinant human IL-2 (250,000 I.U.) was injected
intraperitoneally on days 0, 1 and 2. HLA-A2/Kb transgenic mice
were originally obtained as a kind gift from Dr. Linda Sherman
(Scripts, La Jolla, CA).
Luciferase-based in vivo Bioluminescence Imaging (BLI)
BLI was performed with a Xenogen IVIS 200 Imaging System
(Xenogen/Caliper Life Sciences, Hopkinton, MA). Mice were
anesthetized with 2% isoflurane and injected with D-luciferin
(Xenogen; 1,500 mg per animal) for imaging of fLuc-transduced T
cells. Imaging was performed 5 minutes later and analyzed with
Living Image 2.50 software (Xenogen). The time of acquisition
varied from 3 to 5 minutes. The mean number of photons per
square centimeter per second per steradian in the region of interest
(ROI) was determined on tumor-implanted sites.
Cell culture
In vitro T cell expansion and suppression assays were conducted
in RPMI 1640 media (Mediatech) supplemented with 5 mM
HEPES, 2 mM L-glutamine, penicillin/streptomycin (50 mg/ml
each) (Invitrogen, Carlsbad, CA), 50 mM 2-mercaptoethanol
(Sigma), 5 mM non-essential amino acids, 5 mM sodium pyruvate
(Mediatech), and 10% FCS (Invitrogen). For suppression assays,
cultures were maintained in 200 ml volume in U-bottom 96-well
plates (Costar, Cambridge, MA) incubated at 37uC and 5% CO2.
Cytokine Analysis. Supernatant was collected from TCR trans-
duced Jurkat T cells and analyzed for IL-2 production by standard
sandwich ELISA according to manufacturer recommendations
(BD Biosciences).
Statistics and methods of analysis
Multiple group comparisons were conducted by ANOVA with
Bonferroni post tests. Data analyses utilized GraphPad Prism 5.00
software (GraphPad, San Diego, CA, USA) and values at P,0.05
were deemed significant. Cytokine concentrations were deter-
mined using SOFTmaxH PRO software (Molecular Devices,
Sunnyvale, CA) with four-parameter data analysis.
Supporting Information
Figure S1 Representative FACS plots showing sorted human
CD4+CD25+CD45RA+ Treg and CD4+CD25-CD45RA+
Tconv T cells. Human peripheral blood was collected in sodium
heparin vacutainer tubes. CD4+ T cells were enriched by
incubating whole blood (80 ml) with the CD4 negative selection
cocktail (50 ml/ml) followed by ficoll density gradient centrifuga-
tion. Following CD4 enrichment, cells were incubated with anti-
human CD45RO-biotinylated antibody (0.1 mg/1610ˆ6 cells)
followed by magnetic depletion with streptavidin-coated microbe-
ads. The resulting negatively selected CD4+CD45RA+ T cell
population was stained for CD4, CD25, CD127, and CD45RA
and sorted on a FACS Aria II cell sorter. Shown are pre- and post-
sort expression of (A–C) CD4 (x-axis) and CD45RA (y-axis) and
(D–F) CD127 (x-axis) and CD25 (y-axis) on Treg and Tconv cell
populations, as indicated. (G) CD4+CD45RA+CD127-/loCD25+
Treg (N = 8) or CD4+CD127+CD25- Tconv cells (N = 4) were
analyzed for FOXP3 expression by flow cytometric analysis
following 14 d of in vitro expansion and by real-time PCR method
for percent demethylated at the FOXP3-TSDR. No significant
difference in percent positive by FACS (mean +/2 SD, 92.3+/
29.6) and percent demethylated at the FOXP3-TSDR (90.9+/
215.3) was observed for Tregs, whereas Teff cells exhibited
significantly higher levels of FOXP3 protein (43.6+/225.3) versus
(1.0+/21.3) percent demethylated-FOXP3-TSDR (P,0.05).
Found at: doi:10.1371/journal.pone.0011726.s001 (1.70 MB TIF)
Figure S2 Lentiviral transduction does not alter the capacity of
Tregs to expand or suppress T responder cell proliferation. Fresh
human CD4+CD127-CD25+ T cells were isolated by FACS and
expanded over a 14 day culture period with two rounds of anti-
CD3 & anti-CD28 coated beads and exogenous IL-2 (300 IU/ml).
48 h following activation, either mock treated or lentiviral
transduced cells expressing GFP (9 TU/cell) were expanded to
day 14. At day 14, pSICO-R.eGFP [54] lentiviral transduced cells
were FACS sorted into transgene negative (2), (low), and (high)
expressing cells (A, left column). (B) The suppressive capacity of
each of these sorted cells was then tested at various ratios of Tregs
to T responder cells (1:1, 1/2:1, 1/4:1, 1/8:1, and 1/16:1; where
1 = 5610‘4 T cells) as indicated. For suppression assays,
experiments were conducted in triplicate using freshly isolated
autologous CD3+ T cell depleted APCs (1610‘5 cells/well,
irradiated 3300 rads) in the presence of soluble anti-CD3 (2 mg/
ml) and anti-CD28 (1 mg/ml). (C) The capacity of lentiviral
transduced cells (green triangles) to expand in vitro is not reduced
compared to mock treated Tregs (black squares).
Found at: doi:10.1371/journal.pone.0011726.s002 (0.19 MB TIF)
Figure S3 Expression of tyrosinase TCR constructs by in vitro
expanded human Treg and Tconv cells. Initial expression of
surface TCR, GFP, and FOXP3 following a nine day in vitro
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expansion period for mock or TyrTCR transduced Treg and
Tconv cells. Cells were stimulated with anti-CD3 and anti-CD28
microbeads for 48 hours prior to lentiviral spinoculation. Plots
indicate expression of eGFP (y-axis) and TCR Vb12 or HLA-A2
tyrosinase(368–376) tetramer staining (x-axis) with (A, upper plots)
representing mock transduced cells and (B, lower plots) showing
TyrTCR transduced populations.
Found at: doi:10.1371/journal.pone.0011726.s003 (0.48 MB TIF)
Figure S4 TyrTCR Tregs produce IL-10 in response to peptide
activation and suppress Teff cell production of IL-2 and IFN-c.
TyrTCR or Mock Tregs were incubated with the tumor
infiltrating Teff cell clone (TIL1235) at indicated ratios in the
presence of peptide pulsed HLA-A2.1 T2 APCs. Culture
supernatants following 24 hours were harvested and analyzed for
production of IL-2 (blue), IFN-c (red), and IL-10 (green). Bars
indicate cytokine detected in co-cultures with mock Tregs (filled
bars) and TyrTCR Tregs (open bars).
Found at: doi:10.1371/journal.pone.0011726.s004 (0.80 MB TIF)
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